Clinical Report: The Importance of Multimodal Neuroimaging in Evaluating Monoclonal Antibody Treatments for Alzheimer's Disease

Overview

Revise to emphasize the specific roles of MRI and PET in monitoring treatment effects and side effects.

Background

Alzheimer's disease is the most prevalent neurodegenerative disorder, with a projected increase in cases to 150 million by 2050. The advent of monoclonal antibody therapies targeting β-amyloid marks a significant advancement in treatment, necessitating effective monitoring strategies to manage potential side effects and assess therapeutic efficacy. Multimodal neuroimaging provides essential insights into the disease's progression and treatment response.

Data Highlights

Multimodal neuroimaging techniques, including structural MRI and PET, are essential for monitoring treatment effects and identifying adverse events such as ARIA. These imaging modalities enhance diagnostic accuracy and facilitate personalized treatment approaches.

Key Findings

• Structural MRI (sMRI) identifies cerebral atrophy and amyloid-related imaging abnormalities (ARIA).
• Positron emission tomography (PET) visualizes and quantifies Aβ plaque reduction, serving as an objective biomarker.
• Functional MRI (fMRI) explores brain network connectivity changes post-treatment, though evidence is still emerging.
• AI technologies improve the efficiency of imaging data analysis, aiding clinical decision-making.
• Standardized imaging protocols are necessary to enhance the sensitivity and specificity of neuroimaging methods.

Clinical Implications

Healthcare professionals should integrate multimodal neuroimaging into routine assessments for patients receiving monoclonal antibody therapies for Alzheimer's disease. Regular imaging can help identify treatment-related adverse effects and inform personalized treatment strategies.

Conclusion

Highlight the need for further research in multimodal neuroimaging to improve AD treatment outcomes.

Related Resources & Content

1. Frontiers in Neurology, 2026 -- Integrating neuroimaging and plasma biomarkers to predict preclinical Alzheimer’s disease progression
2. npj Digital Medicine, 2025 -- Multimodal brain network topology and enhanced computer-aided diagnosis in Parkinson’s Disease: a systematic review and meta-analysis
3. Frontiers in Immunology, 2026 -- Anti-Aβ3–10 monoclonal antibody 7B8 improves cognitive function and protects the blood-brain barrier in APP/PS1 mice by regulating the HMGB-1/RAGE/NF-κB pathway
4. Alzheimer's Association Workgroup, 2024 -- Biology-Based Criteria for Diagnosis and Staging of Alzheimer's Disease
5. conexiant — A Two-Biomarker Signal for Alzheimer’s Disease
6. Amyloid‐related imaging abnormalities (ARIA): diagnosis, management, and care in the setting of amyloid‐modifying therapy
7. Alzheimer's Association Workgroup Publishes Biology-Based Criteria for Diagnosis and Staging of Alzheimer's Disease
8. "Lecanemab in early Alzheimer's disease" by Christopher H van Dyck, Randall J Bateman et al.